ADALIMUMAB DOSE ESCALATION IN THE IMPROVED COHORT DOES NOT IMPROVE SHORT-TERM OUTCOMES

Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2024
This article has no abstract
Epistemonikos ID: 218f51e2c2094d3f71d9782ab0792a3ffacba092
First added on: Feb 18, 2025